trial

An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia

NCTId NCT01355952
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 17 (actual)
Sponsored by Yale University
Primary completion 2012-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
17 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2011-05
Primary completion
2012-12
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
Alpha Lipoic Acid

Sponsors

Yale UniversityLead Sponsor

Investigators

1
Cenk Tek, M.D.Principal Investigator

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
17
Phase
NA
Primary Completion Date
2012-12
Status
COMPLETED
relationships
The graph out of here
drug
Alpha Lipoic Acid
drug
lead_sponsor
Yale University
company
indication
Obesity
indication
Weight Loss
indication
Weight Loss
indication
investigator
Cenk Tek, M.D.
person